Description:Ranibizumab is a recombinant humanized monoclonal antibody fragment that specifically targets vascular endothelial growth factor A (VEGF-A), a key protein involved in angiogenesis and vascular permeability. It is primarily used in the treatment of various eye conditions, such as age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina. Ranibizumab is characterized by its small size compared to full-length antibodies, which allows for better tissue penetration. The substance is administered via intravitreal injection, and its mechanism of action involves binding to VEGF-A, preventing it from interacting with its receptors on endothelial cells, thereby reducing vascular leakage and neovascularization. The molecular weight of ranibizumab is approximately 48 kDa, and it is produced using recombinant DNA technology in a mammalian cell expression system. Stability and storage conditions are critical for maintaining its efficacy, as it is sensitive to light and temperature variations. Overall, ranibizumab represents a significant advancement in targeted therapy for ocular diseases.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
